1 document found, page 1 of 1

Evaluating the antitumor activity of selonsertib in pancreatic cancer cell lines

Background: Pancreatic ductal adenocarcinoma (PDAC) is a pathology that ranks seventh among the most common causes of cancer mortality worldwide [1]. Importantly, drug resistance is a major clinical problem for patients with PDAC. Unfortunately, few efficient therapeutic options are available for this type of resistant cancer, and the standard chemotherapy remains gemcitabine or gemcitabine combined with paclit...